Elon Musk Reportedly Eyes June 2026 SpaceX IPO Timed With Planetary Alignment and Birthday 
Volkswagen CEO Oliver Blume Faces Crucial Year as Investors Demand Turnaround Results 
Ford and GM Near Financing Deal to Support First Brands Group During Bankruptcy 
LVMH Investors Watch Earnings Closely as Luxury Recovery Faces New Challenges 
ASML’s EUV Monopoly Powers the Global AI Chip Boom 
First Abu Dhabi Bank Reports 22% Jump in Q4 Profit, Beats Market Expectations 
ANTA Sports to Acquire Major Stake in Puma in €1.5 Billion Deal, Signaling Strategic Revival 
Micron to Expand Memory Chip Manufacturing Capacity in Singapore Amid Global Shortage 
ASML’s EUV Lithography Machines Power Europe’s Most Valuable Tech Company 
Puma’s Historic Rivalry With Adidas Enters a New Era as Anta Deal Signals Turnaround Push 
California Governor Gavin Newsom Launches Review Into Alleged TikTok Content Suppression After U.S. Ownership Deal 
C3.ai in Merger Talks With Automation Anywhere as AI Software Industry Sees Consolidation 
Hyundai Motor Shares Slide After Trump Signals Higher U.S. Tariffs on South Korean Goods 
SoftBank Shares Surge as It Eyes Up to $30 Billion New Investment in OpenAI 
China Approves First Import Batch of Nvidia H200 AI Chips Amid Strategic Shift 
Microsoft Wins Approval to Build 15 New Data Centers in Wisconsin 
Alibaba-Backed Moonshot AI Unveils Kimi K2.5 to Challenge China’s AI Rivals 
LEXINGTON, Mass., May 19, 2017 -- T2 Biosystems, Inc., (NASDAQ:TTOO), a company developing innovative diagnostic products to improve patient health and deliver a strong economic return to healthcare institutions, announced today the company, in collaboration with LabRoots, will host a webinar on May 22, 2017, beginning at 10:00 a.m. PT/1:00 p.m. ET.
The webinar will be hosted by renowned clinical expert Dr. George Alangaden, Senior Staff Physician Director, Transplant Infectious Diseases, Medical Director of Infection Prevention, Henry Ford Hospital System (HFHS). Dr. Alangaden will discuss how HFHS implemented T2MR® and the T2Candida Panel as part of their sepsis protocol for the management of candidemia. He will also share the positive impact T2MR and T2Candida has had at HFHS on patient length of stay and antifungal use.
To read more on this free webinar, learn about the continuing education credits offered, or to register, click here.
About George Alangaden MD, FACP, FIDSA
Dr. Alangaden received his medical degree from the University of Bombay and has since completed post-graduate training in India, the United Kingdom and the United States. Dr. Alangaden is the Director of Transplant Infectious Diseases and Director of Infection Control and Prevention at Henry Ford Hospital and Transplant Institute.
Dr. Alangaden's research interest lies in the epidemiology and outcomes of infections in immunocompromised patients and transplant recipients. He is also involved and well-published in the areas of research related to tuberculosis and nosocomial infections, especially Clostridium difficile.
About T2 Biosystems
T2 Biosystems is focused on developing innovative diagnostic products to improve patient health. With the FDA-cleared T2Dx® Instrument and T2Candida Panel targeting sepsis and a range of additional products in development, T2 Biosystems is an emerging leader in the field of in vitro diagnostics. The Company is utilizing its proprietary T2 Magnetic Resonance technology, or T2MR, to develop a broad set of applications aimed at lowering mortality rates, improving patient outcomes and reducing the cost of healthcare by helping medical professionals make targeted treatment decisions earlier. T2MR enables the fast and sensitive detection of pathogens, biomarkers and other abnormalities in a variety of patient sample types, including whole blood. For more information, please visit www.t2biosystems.com.
About LabRoots
LabRoots is the leading scientific social networking website and producer of educational virtual events and webinars. Contributing to the advancement of science through content sharing capabilities, LabRoots is a powerful advocate in amplifying global networks and communities. Founded in 2008, LabRoots emphasizes digital innovation in scientific collaboration and learning and is a primary source for current scientific news, webinars, virtual conferences and more. LabRoots has grown into the world’s largest series of virtual events within the Life Sciences and Clinical Diagnostics community.
Company Contact: Darlene Deptula-Hicks, T2 Biosystems SVP & Chief Financial Officer [email protected] 603-553-5803 Media Contact: Matthew McKillip, T2 Biosystems [email protected] 518-577-3466 Investor Contact: Tucker Elcock, Teneo Strategy [email protected] 212-886-9319
